Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer

In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab.(1) This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer.

Detalles Bibliográficos
Autores principales: Makhlin, Igor, DeMichele, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245054/
https://www.ncbi.nlm.nih.gov/pubmed/35732147
http://dx.doi.org/10.1016/j.xcrm.2022.100668
_version_ 1784738665401942016
author Makhlin, Igor
DeMichele, Angela
author_facet Makhlin, Igor
DeMichele, Angela
author_sort Makhlin, Igor
collection PubMed
description In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab.(1) This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer.
format Online
Article
Text
id pubmed-9245054
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92450542022-07-01 Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer Makhlin, Igor DeMichele, Angela Cell Rep Med Spotlight In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab.(1) This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer. Elsevier 2022-06-21 /pmc/articles/PMC9245054/ /pubmed/35732147 http://dx.doi.org/10.1016/j.xcrm.2022.100668 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Spotlight
Makhlin, Igor
DeMichele, Angela
Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
title Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
title_full Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
title_fullStr Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
title_full_unstemmed Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
title_short Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
title_sort trastuzumab deruxtecan: an antibody-drug conjugate embracing its destiny in breast cancer
topic Spotlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245054/
https://www.ncbi.nlm.nih.gov/pubmed/35732147
http://dx.doi.org/10.1016/j.xcrm.2022.100668
work_keys_str_mv AT makhlinigor trastuzumabderuxtecananantibodydrugconjugateembracingitsdestinyinbreastcancer
AT demicheleangela trastuzumabderuxtecananantibodydrugconjugateembracingitsdestinyinbreastcancer

Ejemplares similares